Bastani B, Nash J F, Meltzer H Y
Psychobiology Clinic, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Arch Gen Psychiatry. 1990 Sep;47(9):833-9. doi: 10.1001/archpsyc.1990.01810210041006.
To examine further the serotoninergic system in obsessive-compulsive disorder (OCD), the plasma concentrations of cortisol and prolactin and the behavioral responses after oral administration of MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine), a serotonin agonist, and placebo were studied in 17 patients with OCD and nine normal controls. The two groups did not differ significantly in basal plasma prolactin or cortisol levels. Nevertheless, both the prolactin and cortisol response to oral administration of MK-212 (20 mg) were significantly blunted in the patients with OCD compared with those of the normal controls. MK-212 did not affect the intensity of OCD symptoms. However, MK-212, as compared with placebo, produced slight but statistically significant increases in self-ratings of nausea, dizziness, anxiety, feeling strange, and mixed feelings of calmness and restlessness, as well as depression and feeling high. These behavioral ratings were not significantly different in patients and normal controls. These findings are consistent with previous reports of diminished serotoninergic responsivity in OCD and raise the possibility of subsensitivity of at least some serotonin receptors in this disorder.
为了进一步研究强迫症（OCD）中的血清素能系统，我们对17名强迫症患者和9名正常对照者进行了研究，检测了口服血清素激动剂MK-212（6-氯-2-[1-哌嗪基]-吡嗪）和安慰剂后血浆皮质醇和催乳素的浓度以及行为反应。两组在基础血浆催乳素或皮质醇水平上无显著差异。然而，与正常对照者相比，强迫症患者口服MK-212（20毫克）后催乳素和皮质醇反应均明显减弱。MK-212对强迫症症状的强度没有影响。然而，与安慰剂相比，MK-212在恶心、头晕、焦虑、感觉怪异、平静与不安的混合感觉以及抑郁和兴奋感的自我评分上产生了轻微但具有统计学意义的增加。这些行为评分在患者和正常对照者中无显著差异。这些发现与先前关于强迫症中血清素能反应性降低的报道一致，并提出了该疾病中至少一些血清素受体存在敏感性降低的可能性。
